Product Description
Mechanisms of Action: DLL4 Inhibitor, VEGF Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: OncXerna Theraputics, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer
Phase 2: Triple Negative Breast Cancer|Ovarian Cancer|Colorectal Cancer|Gastrointestinal Cancer
Phase 1: Colorectal Cancer|Oncology Solid Tumor Unspecified|Fallopian Tube Cancer|Peritoneal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03030287 |
B83-002 | P1 |
Completed |
Peritoneal Cancer|Fallopian Tube Cancer |
2020-04-01 |
2020-04-11 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT03035253 |
B83-003 | P1 |
Terminated |
Colorectal Cancer |
2018-09-01 |
2019-03-21 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT02298387 |
B83-001 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2017-05-23 |
2019-03-20 |
||
NCT05453825 |
ONCX-NAV-G201 | P2 |
Unknown status |
Colorectal Cancer|Gastrointestinal Cancer|Ovarian Cancer|Triple Negative Breast Cancer |
2024-04-15 |
2025-01-03 |
Primary Endpoints|Treatments|Trial Status |
|
NCT05043402 |
ONCX-NAV-G301 | P3 |
Unknown status |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer |
2023-11-15 |
2024-08-17 |
Primary Endpoints|Treatments|Trial Status |
|
2021-001933-38 |
REVELARE | P3 |
Terminated |
Fallopian Tube Cancer|Ovarian Cancer|Peritoneal Cancer |
2023-06-30 |
2025-05-06 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/12/2026 |
News Article |
Mereo BioPharma Provides Corporate Update |
|
12/29/2025 |
News Article |
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta |
|
08/19/2025 |
News Article |
āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2 |
|
03/05/2025 |
News Article |
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference |